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Summary.-The possible use of liposomes (phospholipid vesicles) to direct cytotoxic
drugs to tumours has led us to investigate the tissue localization of i.v. injected
99m-Tc-labelled liposomes in cancer patients. Twenty mg or300 mgdosesofliposomal
lipid (7:2:1 molar ratio of phosphatidylcholine:cholesterol:phosphatidic acid) were
used in a study of 13 patients with advanced cancer and one with polycythaemia rubra
vera (PRV). In all cases except the patient with PRV the major site of uptake of the
label was the liver and spleen. In the patient with PRV the liver uptake was greatly
reduced and the major site of uptake was found in regions corresponding to marrow.
With the exception of one patient with a primary hepatoma, there was no significant
tumour uptake of the label.
LIPoSOMES are small phospholipid
vesicles (25 nm-5 lum diameter) consisting
of one or more sealed concentric lipid
bilayers separated by aqueous compart-
ments (Bangham et al., 1965). Their
structure offers a biodegradable vehicle
for the carriage ofcytotoxic agents trapped
either in their aqueous or lipid layers
(Juliano & Stamp, 1978; Papahadjopoulos,
1978). Animal experiments suggest that
liposomally entrapped antineoplastic
drugs may prove useful in cancer chemo-
therapy, and may offer advantages over
more conventional methods of chemo-
therapy (Rutman et al., 1977; Kobayashi
etal., 1977; Kosloski etal., 1978). However,
there appears to be some doubt as to the
exact mechanism by wlhich liposomally
entrapped drugs may be more effective
than non-entrapped drugs. Liposomally
entrapped drugs may exert their effects
either by a prolongation of the plasma
half-life of the cytotoxic drug (Colley &
Ryman, 1975; Juliano & Stamp, 1978) or
liposomes may impart an increased tumour
affinity to the entrapped drug by the
liposomes actively localizing in the
tumour tissues (Dapergolas et al., 1976).
However, liposomes injected i.v. are
mainly taken up by the cells of the liver
and spleen (Gregoriadis & Ryman, 1972).
Specific accumulation of liposomes in
tumours, and particularly in tumour cells,
would be of considerable advantage in
improving the selectivity of anti-cancer
drugs. Such a possibility seems feasible in
view of reports that some tumour cells
have a high endocytic activity (Busch et
al., 1961; Ghose et al., 1962; Easty et al.,
1964; Mego & McQueen, 1965; Trouet et
al., 1972) which may enhance uptake of
liposomes. Previous studies with animal
models have shown that tumour localiza-
tion of liposome markers is possible by a
careful selection of the size and membrane
properties of the liposome (Dapergolas
et al., 1976; Richardson et al., 1977,
1978b). There have also been two reports
on the possible tumour localization of
liposomal markers in patients (Gregoriadis
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et al., 1974; Segal et al., 1976). In one of
these (Gregoriadis et al., 1974) localization
of the label was seen in tumour tissue.
The other report (Segal et al., 1976) was
inconclusive. In the first of these, 1311-
labelled serum albumin was used as a
marker for the liposomes and in the
second lllln-labelled bleomycin was used
as a liposomal marker. Recently Richard-
son et al. (1978a) have shown that lipo-
somes can be labelled with 99mTe, a
versatile nuclide extensively used in
nuclear medicine, with chemical and
physical properties ideally suited for
labelling and radionuclide imaging
(Subramanian et al., 1975). Animal studies
using such labelled liposomes have shown
that tumour localization can be achieved,
and that this can be visualized with a
gamma camera (Richardson et al., 1978a).
Pharmaceutical preparations of liposomes
consisting of neutral lipids have been pre-
pared, and the distribution of an i.v.
injected 99mTc-labelled preparation has
been reported in a patient with a primary
hepatoma, but without any significant
tumour localization (Richardson et al.,
1978b).
The toxicity of liposomes of several
lipid compositions has been investigated
in mice (Adams et al., 1977). Other investi-
gators have also used liposomes containing
a 7:2:1 molar ratio of egg phosphatidyl-
choline, cholesterol and phosphatidic acid
without any observable toxic effects in
rats (Gregoriadis, 1976) or man (Gregori-
adis et al., 1974; Tyrrell et al., 1976;
Belchetz et al., 1977). However, some lipid
compositions used in making liposomes
have had toxic side effects (Bruni et al.,
1976; Adams et al., 1977; Steger &
Desnick, 1977). Animal tumour studies
have shown that very small negatively
charged liposomes appear to concentrate
well in tumour tissue (Richardson et al.,
1978a). We now report the results ob-
tained from 14 patients injected with
99mTc-labelled negatively charged lipo-
somes, composed of a 7:2:1 molar ratio of
phosphatidylcholine:cholesterol:phospha-
tidic acid.
MATERIALS AND METHODS
Preparation ofltiposomes -Batches ofnega-
tively charged (anionic) liposomes, composed
of a 7:2:1 molar ratio of egg phosphatidyl-
choline (lecithin) cholesterol : phosphatidic
acid, were prepared in a sterile, pyrogen-free
form by the method previously described by
Richardson et al. (1978b). Two different dose
levels ofliposomes were used in these studies;
either of 20 or 300 mg of lipid per patient.
Liposomes were prepared as required and
stored at 4°C for periods of up to 6 weeks
under an atmosphere of N2. Before labelling
with technetium, each dose of liposomes was
further sonicated, using a Megason Ultrasonic
bath, for between 4 and 5 h to break up any
aggregates.
Preparation of 99mTc-labelled liposomes.-
Two methods of labelling the liposomes with
99mTc were used. In the earlier studies using
20mg doses of lipid, a stannous chloride
method was used as follows. About 670 mg of
Analar SnCl2.2H20 was dissolved in 100 ml
of 02-free water (suitable for injection) pre-
pared by passing 02-free N2 through a sterile
0 22,tm Millipore filter, and then bubbling
this for at least 10 min before the addition of
the stannous chloride. The bubbling was coIn-
tinued during the course of the rest of the
procedure. After the stannous chloride was
dissolved the solution was sterilized by pass-
ing through a sterile 0-22[tm Millipore filter
and 0-5ml aliquots were dispensed into
evacuated multidose vials, which were stored
at 4°C and used within 3 weeks. The whole of
the preparative procedure was performed in a
laminar-flow cabinet, and all batches were
tested for pyrogenicity and sterility, as pre-
viously described (Richardson et al., 1978a).
Liposomes were labelled simply by adding
1 ml of liposomes (20 mg lipid) in 0.9%
saline and 1 ml (15-20 mCi) of sodium per-
technetate simultaneously to the 0 5 ml of
ScCl2 solution and mixing well. The mixture
was allowed to stand for 15 min before use. A
small portion of each preparation of lipo-
somes used for the patient studies was tested
for sterility. In later patient studies using
300mg doses oflipid, the method ofpreparing
the SnCl2 was modified to increase its shelf-
life. After dispensing the 0-5ml aliquots of
SnCl2, prepared as above, the samples were
freeze-dried and then further sterilized by
gamma radiation (5 M rad over a period of
26 h). 3 ml of liposomes (300 mg lipid) in
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0.9% saline and 0-5 ml (15-20 mCi) ofsodium
pertechnetate were injected simultaneously
through the rubber stopper of the vial,
mixed with the solid stannous chloride and
left to stand for at least 15 min before use.
Selection and injection of patients in the
study.-All patients had histologically con-
firmed tumours as listed in Table I. Informed
consent from all patients was obtained before
the liposomes scans were performed.
Potassium perchlorate (400 mg) was given
orally to Patients la, 2 and 4 before liposome
administration to ensure thyroid protection
in the unlikely event of the technetium
detaching from the liposomes. Liposomes
labelled with 15-20 mCi of technetium were
injected i.v., usually into a vein in the arm,
but in one case (Patient 6) the liposomes
were injected as a bolus through an i.v. drip
into a vein in the leg. Before injection all
doses of liposomes were compared with a
sodium pertechnetate (99mTcO4-) standard
to determine the injected dose and relative
activity of blood and urine samples taken
after injection.
Blood clearance of the 99mTc label.-The
blood clearance of the 99mTc label was
measured by taking blood samples at inter-
vals after injection of the 99mTc-labelled
liposomes (see Table II). Blood samples
were collected into heparinized containers
and lml samples of whole blood were used to
determine radioactivity, and compared to the
standard solution of sodium pertechnetate
(99mTcO4--) used to determine the injected
dose.
Dynamnic study of liver uptake of 99mTc
label.-Dynamic studies were made of the
liver uptake ofthe 99mTc label in some ofthe
patients. Where this was done before injec-
tion, the patients were seated or placed
supine with the gamma camera (Nuclear
Enterprise wide field Mark V) centred over
the posterior aspect ofthe lower thoracic and
upper lumbar region. The area visualized
included most of the liver, spleen, kidneys,
spine, stomach, lungs and heart. Liposomes
were injected and the change in distribution
ofradioactivity was recorded for 30 min with
a Varian data-processing system linked to
the gamma camera. The time-radioactivity
curve over the organs of interest was com-
puted from the data recorded (see Fig. 1).
Tissue distribution of the 99mTc label.-At
-5 and 24 h after injection, whole-body
images showing the tissue distribution of
radioactivity were made of the patients with
an Elseint double-headed whole-body scan-
ner. The distribution of the 99mTc label was
recorded using a Varian computerized data-
processing unit. The images of the radio-
active distribution were then displayed on a
television screen and a photographic record
made. Some of these pictures are shown in
Figs. 2 and 3.
Excretion of the 99mTc label in the urine.-
Samples of urine were collected from two
patients (2 and 3) in 6-hourly periods over
the 24 h after injection, and the volume and
99mTc content determined for comparison
samples with the 99mTc standard. In this way
the percentage of the injected dose excreted
was determined for each of the samples (see
Table III).
RESULTS
Table I gives details of the 14 patients
selected for this study. Ten subjects had
solid tumours with widespread metastases,
2 had primary hepatomas with disease
confined to the liver and 2 had haemato-
logical malignancies. In the case of
Patient 1 (see Table I) two studies were
made, once with a 20mg dose ofliposomes
(Study la) and 9 months later with a
300mg dose of liposomes (Study lb).
Patients 2-9 each received a 20mg dose of
liposomes, whilst Patients 10-14 each re-
ceived a 300mg dose (see Table II). A
description of the histologically confirmed
tumour, the primary site, sites of second-
ary metastases where known, and the
interval between therapy and scanning
are also given in Table I. Only 3 of the
patients (6, 9 and 10) had received no
chemotherapy before the study, and in 5
ofthe remaining 12 studies (la, 3, 4, 7 and
13) no chemotherapy had been given for
over 1 month. Details of the major drug
regimes used for each patient are given in
Table I.
Table II shows the blood clearance of
the 99mTc label as determined in 10 of the
patients. The initial blood sample taken at
-.5-10 min after injection was called the
100% value, and all other samples were
compared with this. Few blood samples
were taken, but it appears that there is an
initial rapid clearance with a half-life of
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TABLE I.-Details ofpatients studied
Patient
r-
A
No. Sex
1. Y (a)
(b)
2. y
3. c3
4. d
5. 6'
6. 6'
7. CT
8. y
9. y
Tumc
Hepatoma
our or disease
Choriocarcinoma
Hepatoma
Polycythaemia rubra vera
Hypernephroma
Acute myeloblastic
leukaemia
Teratoma of testis
Choriocarcinoma
Adenocarcinoma of breast
Carcinoma of bronchus
Haemangiopericytoma
Kaposi's sarcoma
13. y Choriocarcinoma
14. y Choriocarcinoma
Known sites of disease
Liver
Uterus, both lungs, brain
Liver
Spleen liver, marrow
Kidney (L), both lungs
Marrow
Testis (R) removed, lung (R)
Uterus, liver, both lungs
Breast (R), axillary lymph
nodes (R)
Lung (L), brain (R)
Thigh (L), both lungs
Leg (R) amputated, lung (L),
liver, inguinal lymph
nodes (R)
Uterus, both lungs, pelvis
Uterus, kidney, both lungs
Interval
between
therapy
and
Drug therapy scanning
(a) Adria 4 months
(b) VP 16-213 1 day
7 Drug comb 3 days
CB 10252 35 days
Busulphan 18 months
Cis plat 13 days
None
VCR/MTX/Bleo 28 days
VCR/MTX/Cis plat 2 days
None
None
VLBE/Chlor/Adria 21 days
Razoxin 26 days
(ICRF 159)
7 Drug comb. 28 days
VP 16-213 1 day
Abbreviations:
Adria=Adriamycin. Bleo=Bleomycin. CB 10252=Alkylating agent from Chester Beatty Research
Institute, activated by tissue azoreductase. Chlor=Chlorambucil. Cis plat=Cis diammine dichloroplatinum.
7 Drug comb=Hydroxyurea, vincristine, methotrexate, actinomycin D, cyclophosphamide, adriamycin and
melphalan. MTX=Methotrexate. VCR=Vincristine. VLBE=Vinblastine. VP 16-213=Semi-synthetic
podophyllotoxin epoxide.
TABLE II.-Dose levels and blood clearance of 99mTc label associated with anionic liposomes
Percent of initial blood sample
(Time min)
ND
ND
ND
100 (4)
100 (10)
100 (7)
100 (5)
100 (8)
100 (14)
100 (7)
100 (9)
100 (9)
ND
ND
ND
ND
100 (32)
ND
86 (35)
96 (30)
90 (29)
74 (26)
82 (50)
72 (30)
72 (25)
82 (55)
ND
ND
(Time h)
ND ND
ND ND
74 (3) 24 (23)
34 (6) 5 (26)
ND 10 (24)
ND 9 (24)
ND 12 (24)
ND 0-2 (24)
ND 18 (20)
28 (5) 10 (24)
39 (5) 10 (24)
27 (5.5) 2-5 (24)
ND ND
ND ND
ND not done.
,3 h, followed by a slower clearance with
a half-life of -8-12 h. Patients given the
higher dose of lipid had a slightly more
rapid initial blood clearance.
Table III shows the urinary excretion
of the technetium label over the first 18 h
(Patient 3) and 24 h (Patient 2). In both
cases 25-30% of the injected label was
excreted in the urine over this period.
Fig. 1 is the computer-drawn time-
activity curves over the regions of the
liver (L), heart (H) and other tissues which
were used as a background (B) during the
course ofthe first 30 min after injection of
10.
11.
12.
6'
Y
6'
Patient
(see
Table I)
la
lb
2
3
4
5
6
7
9
10
11
12
13
14
Dose of
lipid
given
(mg)
20
300
20
20
20
20
20
20
20
300
300
300
300
300
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TABLE III. Exc
in
Patient
2
3
retion of the 99mTc label over the region of the heart (H). The liver
the urine continues to take up activity rapidly over
Time a period of 15 min, when the uptake (luring % becomes slower. No accumulation of
which inijected activity was observed in any of the other
urine (lose
collecte(d exerete(d organs, including the kidneys and
(h) in urine stomach.
0-6 8 Fig. 2 shows the whole-body scans of
6 12 13 Patient 2 (see Table I) at (a) 41 h and (b)
12-24 92
o0- 10 24 h after injection, and shows the tissue
6-12 6 distribution of the technetium label. The
12-18 8 first scan shows high activity in the liver
and also the heart, lungs and marrow. The
lttozon.-n Qhnlxrz +t,ho ,fF,,tf, nf hinntl iu ulCl UUI1 i Nvall PlUJWS uiUl; lUtiUUD V1 uJ1VtJ
clearance and tissue deposition of the
label at 24 h. The activity in the lungs and
heart had diminished (the average fall in
activitv between these times for the
patients studied was ,-75%). The activity
appears to have accumulated greatly in
the liver and remains to some extent in
the marrow. There appears to be no sig-
nificant accumulation of radioactivity in
the primary tumour (choriocarcinoma) or
in secondary metastases (lungs and brain)
at either time scanned.
Whole-body scans showing the organ
distribution of the 99mTc label in 3 of the
patients at 24 h are shown in Fig. 3. In all
of the patients, excluding Patient 3 who
had a large hepatoma and Patient 4 with
polycythaemia, the normal liver tissue
was the main site of uptake of the label.
This was true for patients given both high
and low doses of lipids. In the hepatoma
Fi(m:. 1. Variation
regions of the H
(background tis
computerizedl da
25 min after i.v
99mTc-labelledl ii
(choriocarcinoma
the liposomes inl
the uptake of the
blood clearance o
the values record
during this perio(
the activity rapic
This is paralleled
10 1 20 25 patilent (Fat,lent 3) the main site ot uptake
TIME (MIN) was the grossly enlarged spleen; some of
is in radoattythe label was also seen in the salivary 1S inl ra(lioactivity ovei'
I (heart), L (liver) afl(l B glands (see Fig. 3a). Liver and spleen ,suies) as obtaine(d from uptake were greatly reduced in Patient 4
,ta recoiCle(I ovei the fir-st * * * - injection of 300 mg of with polycythaemia and the majority of
iposomes into Patient 14 radioactivity remaining in this patient,
was found in the marrow and kidnev
(Fig. 3b).
to Patient 14. It shows Patient la (Fig. 3c) shows technetium
liposomal label and the localization in the normal liver tissue and
if 99mTc, represented by also in the area of the tumour. However,
ed over the heart region using an alternative scanning agent (tech-
A. The liver (L) localizes netium stannous colloid) shortly before
lly over the first 5 min. the liposome study, there was no visible
by a rapid fall in activity tumour localization (Fig. 3d). An attempt
11.39
V)
..-C
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n
n
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FIG. 2.-Whole-body scans of Patient 2 (choriocarcinoma) showing tissue distribution of the 99mTc
label at (a) 4j h and (b) 24 h after injection of 20 mg ofliposomal lipid labelled with 99mTc (details
in Materials and Methods). B=marrow; H=heart; L=liver.
to repeat the observed apparent liposome
localization in the tumour at a later date
using a 300mg dose oflipid shortly after a
course of chemotherapy was negative. In
the case of Patient la (Fig. 3c) there
appears to be axillary lymph node
localization of a small portion of the lipo-
somes which had inadvertently been
extravasated during administration. With
the possible exception of Patient la (Fig.
3c) who had a primary hepatoma, there
was no evidence of any significant tumour
localization of the radioactivity after in-
jection of 99mTc-labelled liposomes.
DISCUSSION
There have been two studies, using
animal tumour models, showing tumour
localization of labelled liposomes (Neerun-
jun et al., 1977; Richardson et al., 1977)
and one study in which no tumour
localization was observed (Anghileri et al.,
1976). Patient studies have also been
reported (Gregoriadis et al., 1974; Segal
et al., 1976) but in only one of these
(Gregoriadis et al., 1974) has there been a
significant tumour accumulation of the
liposome label, in a single patient with
cancer. From these data and the present
relatively negative results it would appear
that there are differences between the rat
tumour models and the human tumours
studied, and this could be due to factors
related to the tumours themselves or to
differences in the physical or behavioural
properties of the liposomes.
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d
FIG. 3.-Whole-body scans 24 h after injection with 20 mg of liposomal lipid labelled with 15-20 mCi
99mTc (for details see Materials and Methods). (a) Patient 3 (hepatoma G=salivary glands; L=liver;
S=spleen; T=tumour. (b) Patient 4 (polycythaemia rubra vera) B=marrow; L=liver. (c) Patient
la (hepatoma) I=injection site; L=liver; N=axillary lymph nodes; T+ tumour. (d) Conventional
liver scan of patient 1 after injection of 99mTc-stannous colloid. T=tumour.
The endocytic activity of certain
tumours could be related to their growth
rates, the rapidly proliferating tumours
having a higher endocytic activity. Most
human tumours studied were more slowly
growing tumours than the transplantable
animal tumours studied. There is also the
possibility of large differences in surface
properties between animal and human
tumour cells. Such differences may mani-
fest themselves in variations in liposome
receptor regions on the surface of tumour
cells. Cytotoxic chemotherapy may also
damage endocytosis, and there have been
reports that cyclophosphamide and other
cytotoxic drugs suppress phagocytosis
Sharbaugh & Grogan, 1969; Magarey &
Baum, 1970; Lokich et al., 1974). Drug
treatment and length of time between
chemotherapy and liposome scans in our
studies were recorded (Table I). However,
no relationship between the behaviour of
the 99mTc label and the type of drug
therapy given or the interval between
treatment and scanning was found.
The rate of metabolism ofthe liposomes
may be different in the Walker 256 rat
tumour used in the animal model de-
scribed by Richardson et al. (1977, 1978a)
and the human tumours. Lack of accumu-
lation of liposomes in the human studies
could conceivably be due to a rapid turn-
over of the liposome components, re-
leasing the 99mTc label from the tumour
cells.
The possibility that differences in the
physical properties of the liposomes used
for animal and patient studies, due to the
slight differences in preparation and
storage of the patient doses of liposomes,
led to changes such as fusion or de-
terioration of the lipid components was
considered. However, injection of 6
Walker tumour-bearing rats with lipo-
somes prepared for Patient la (Table I)
showed that this was probably not the
case, and the previously observed tumour
localization of the label was found to be
unchanged.
Liposomes are known to interact and
attach to plasma proteins, oil-macro-
globulins in human plasma and a2-
4142 V. J. RICHARDSON ET AL.
macroglobulins from rat plasma (Black &
Gregoriadis, 1977). It is also known that
plasma proteins can modify liposome pro-
perties (Black & Gregoriadis, 1977; Tyrrell
et al., 1977). These variations in inter-
actions with plasma proteins could ex-
plain why liposomes are not taken up by
tumours in man, but are in rats.
The development of the technetium-
labelling technique reported in this paper
has allowed us to follow the tissue dis-
tribution ofliposomes using neither biopsy
nor necropsy, and to determine whether
tumour localization has taken place. It
may prove useful in evaluating whether
or not liposomes can be modified in such a
way as to make them more tumour-
specific in man. Because 99mTc has such a
short half-life, several scans could be made
safely in a single patient with different
liposome preparations. The radiation
hazard to the patient would be low.
The studies reported in this paper in-
dicate that the distribution of 99mTc-
labelled liposomes in normal tissues of
man and rats is similar. This included
blood clearance, liver accumulation and
excretion of the 99mTc label (Richardson
et al., 1977). However, in man the simi-
larity excludes tumour localization, ex-
cept perhaps in the one case of Patient la
with a primary hepatoma. It may be
noted that this was not found to be repro-
ducible (Study lb) using a larger dose of
liposomes. However, the second of these
studies was made the day following the
end ofa course ofcytotoxic chemotherapy
and this possibly influenced the results.
In our rat study (Richardson et al.,
1977, 1978b) we reported that many
factors influenced the tumour localization
of the 99mTc label. These included lipid
composition, liposome charge, size and
lipid fluidity. Further studies in cancer
patients are required to examine the
importance of each of these factors, as
well as extending the range of tumours
studied.
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